Gilead shares rise on improved Sovaldi sales predictions; Novartis sues alleging Zortress patent infringement;

@FiercePharma: Merck KGaA negotiates huge production deal with Lupin. ICYMI yesterday from FiercePharmaManufacturing | Follow @FiercePharma

@EricPFierce: MannKind says it and partner Sanofi can fatten their margins on Afrezza by using Sanofi API. Story | Follow @EricPFierce

@CarlyHFierce: AstraZeneca sends James Van Der Beek 'camping' to promote flu vaccination. Article from FiercePharmaMarketing | Follow @CarlyHFierce

> Shares of Gilead Sciences ($GILD) stock rose in afternoon trading Tuesday as FBR analyst Andrew Berens raised his Q3 Sovaldi sales forecast. Report

> AstraZeneca ($AZN) has inaugurated a new Global Technology Center in Chennai, India, to develop its IT capability. Report

> Novartis ($NVS) has sued generics maker Roxane Laboratories over patent infringement on organ rejection drug Zortress. More (sub. req.)

> Almost 90 lives could be saved every year if almost all teenage girls were given HPV vaccines, experts say. Report

> Two U.S. lawmakers are calling for action to curb antibiotic use on farms. More

> A public petition to force Roche ($RHHBY) to lower the cost of breast cancer drug Kadcyla has been spread online by a British disease survivor. More

> The risk of endophthalmitis is 65% higher following treatment with Bayer and Regeneron's ($REGN) Eylea than treatment with Novartis ($NVS) and Roche's ($RHHBY) Lucentis, new data show. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Researchers at Harvard's Wyss Institute develop dialysis device to fight Ebola. Article | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of #polio vax application. More | Follow @MichaelGFierce

@VarunSaxena2: ICYMI: St. Jude halts Portico TAVR implants over safety concerns. Story | Follow @VarunSaxena2

@EmilyWFierce: IVF grows by leaps and bounds as 1% of U.S. babies are conceived through assisted reproductive technology. Story via The Atlantic | Follow @EmilyWFierce

> Medtronic unloads instrument lines to Integra for $60M. Story

> FDA takes step toward standardized medical device labeling. Article

> Avinger raises $35M for PAD catheter that combines imaging and treatment. News

Biotech News

@FierceBiotech: From yesterday's FierceBiotechResearch: Human stem cells can be 'reset' to their earliest state. Article | Follow @FierceBiotech

@JohnCFierce: Novo is looking to base a new obesity R&D group in Seattle, which would be great for them. More from Bloomberg | Follow @JohnCFierce

@DamianFierce: Oxygen Bio will soon be Tenax Therapeutics. $OXBT to $TENX. Release | Follow @DamianFierce

@EmilyMFierce: Naturally occurring antibiotic found in human bacterial colony. FierceBiotech Research story | Follow @EmilyMFierce

> Gilead's oncology contender comes up short in pancreatic cancer. Story

> Sutro adds Merck KGaA to its roster of marquee 'armed antibody' partners. More

> Tokai pockets $97M in IPO cash to get its cancer drug into Phase III. Article

> Sanofi partners with MyoKardia on a 'totally new' approach to heart disease. Report

Drug Delivery News

> Researchers deploy nanoparticles that can alter packaging of DNA. Item

> Vaxxas' nanopatch garners WHO support in search of polio vax application. Story

> Civitas, NeuroDerm, EyeGate to pursue IPO dreams, combined $165M on the line. Article

> Drug delivery specialist Genisphere receives an additional $2M in funding. News

> Market research firm: RNA-based drugs to exceed $1B in sales by 2020. Report

Diagnostics News

> Gene-sequencing leukemia research could boost Dx and treatment for kids with a rare disease subtype. More

> Pittsburgh outfit launches blood Dx to measure pediatric transplant rejection risk. Report

> Belgium's VolitionRx touts positive early results for noninvasive colon cancer Dx. Story

> Amarantus scores a small victory in the advance of its Alzheimer's Dx test. More

> BG Medicine slashes staff before launching automated version of heart failure test. Article

Pharma Marketing News

> AZ faces market-making task to capitalize on Movantik's edge in OIC. Article

> Sanofi, MannKind say cutting insulin costs will make Afrezza more competitive. Item

> First-to-market launch? Bonus--but double bonus if you're Big Pharma. More

> AstraZeneca sends James Van Der Beek 'camping' to promote flu vaccination. Story

> Xtandi field force gets a staffing boost for market-share battle with Zytiga. Article

And Finally... Sitting less can slow the aging process within cells, and standing up--even if you're standing still--can be good for you as well, two new studies show. More

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.